The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss

Journal of Occupational and Environmental Medicine

Volumn 47, Issue 11, 2005, Pages 1167-1173

  Kwong, W Jacqueline ^a,b,e   Taylor, Frederick R ^c   Adelman, James U ^d  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PARK NICOLLET INSTITUTE   (United States)

^d Headache Wellness Center   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; IBUPROFEN; ISOMETHEPTENE MUCATE; PARACETAMOL; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EMPLOYEE; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PRODUCTIVITY; RETROSPECTIVE STUDY; UNITED STATES;

EID: 27844606371     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000174296.46911.79     Document Type: Article

References (32)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
2. Mannix LK. Epidemiology and impact of primary headache disorders. Med Clin North Am. 2001;85:887-895.
3. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39:320-327.
4. Stang P, Cady R, Batenhorst A, et al. Workplace productivity: a review of the impact of migraine and its treatment. Pharmacoeconomics. 2001;19:231-244.
5. Osterhaus JT, Gutterman DL, Plachetka. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2:67-76.
6. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813-818.
7. Burton WN, Conti DJ, Chen CY, et al. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med. 2002;44:523-529.
8. Gerth WC, Sarma S, Hu XH, et al. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med. 2004;26:48-54.
9. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manag Care. 1996;2:1407-1416.
10. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2000;75:782-789.
11. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998;158:1013-1018.
12. Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther. 1999;21:190-204.
13. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache. 1996;36:137-143.
14. Cady RK, Sheftell F, Lipton RB, et al. Effects of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000;22:1035-1048.
15. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache. 2000;40:792-797.
16. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78:1214-1222.
17. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.
18. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703-1709.
19. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55:27-36.
20. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26.
21. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, et al. 2003 Wolff Award: possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache. 2003;43:704-714.
22. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neural Sci. 1999;26:S12-19.
23. Headache Classification Committee of the International Headache Society. Classification of headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
24. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004;24:925-933.
25. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20:1465-1472.
26. Klapper J, Lucas C, Rosjo O, Charlesworth B. ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004;24:918-924.
27. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache. 2003;43:1075-1079.
28. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache. 2002;42:28-31.
29. Halpern MT, Lipton RB, Cady RK, et al. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache. 2002;42:984-999.
30. Legg RF, Sclar DA, Nemec NL, et al. Cost benefit of sumatriptan to an employer. J Occup Environ Med. 1997;39:652-657.
31. Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy. 2000;20:1356-1364.
32. Cady RK, Sheftell F, Lipton RB, et al. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther. 2001;23:284-291.